
Teleflex (TFX) Stock Forecast & Price Target
Teleflex (TFX) Analyst Ratings
Bulls say
Teleflex is a leader in the medical technology industry with a strong focus on enhancing clinical benefits and reducing procedural costs. Its diverse range of products and global presence make it well-positioned for continued growth. Additionally, the company's unique and differentiated resorbable metallic scaffold, Freesolve, could potentially drive significant earnings growth in the future. While there are some risks to consider, such as slower than expected growth or delays with the Biotronik integration, the company's strong financial performance, progress in capital deployment, and potential for future acquisitions suggest a favorable outlook.
Bears say
Teleflex is facing challenges with the integration of Biotronik and its capital deployment strategy may temporarily boost earnings, but ultimately the road to significant earnings growth will be longer than expected. With a higher forecast and P/E multiple in comparison to its peers, Teleflex's current stock price is not justified, even considering potential interest from private equity firms for a takeout. The company's operating margin is expected to normalize and see significant EPS growth in 2027, but that is still a few years away.
This aggregate rating is based on analysts' research of Teleflex and is not a guaranteed prediction by Public.com or investment advice.
Teleflex (TFX) Analyst Forecast & Price Prediction
Start investing in Teleflex (TFX)
Order type
Buy in
Order amount
Est. shares
0 shares